| # | Drug | Count |
|---|---|---|
| 0 | CARBOPLATIN | 22 |
| 1 | METHOTREXATE SODIUM | 20 |
| 2 | METHOTREXATE | 19 |
| 3 | PACLITAXEL | 16 |
| 4 | ADALIMUMAB | 15 |
| 5 | PACLITAXEL (AIBUMIN-BOUND) | 14 |
| 6 | BEVACIZUMAB | 13 |
| 7 | INFLIXIMAB | 13 |
| 8 | MIRVETUXIMAB SORAVTANSINE | 13 |
| 9 | LENALIDOMIDE | 10 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | MIRVETUXIMAB SORAVTANSINE | 13 | 0.0072 |
| 1 | HYDROCORTISONE ACETATE AND PRAMOXINE HYDROCHLORIDE | 1 | 0.0047 |
| 2 | DROSPIRENONE AND ESTRADIOL | 1 | 0.0019 |
| 3 | CLOMIPHENE CITRATE | 1 | 0.0007 |
| 4 | DACTINOMYCIN | 1 | 0.0005 |
| 5 | MEFENAMIC ACID | 1 | 0.0005 |
| 6 | BEVACIZUMAB-AWWB | 2 | 0.0004 |
| 7 | IMIGLUCERASE | 2 | 0.0004 |
| 8 | NEOMYCIN OINTMENT | 1 | 0.0004 |
| 9 | AMANTADINE HYDROCHLORIDE | 2 | 0.0004 |
| # | Drug class | Count |
|---|---|---|
| 0 | Platinum-based Drug [EPC] | 27 |
| 1 | Tumor Necrosis Factor Blocker [EPC] | 21 |
| 2 | Folate Analog Metabolic Inhibitor [EPC] | 19 |
| 3 | Microtubule Inhibitor [EPC] | 18 |
| 4 | Nonsteroidal Anti-inflammatory Drug [EPC] | 17 |
| 5 | Vascular Endothelial Growth Factor Inhibitor [EPC] | 15 |
| 6 | Corticosteroid [EPC] | 12 |
| 7 | Estrogen [EPC] | 12 |
| 8 | Vitamin C [EPC] | 12 |
| 9 | Thalidomide Analog [EPC] | 10 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Actinomycin [EPC] | 1 | 0.0005 |
| 1 | Hydrolytic Lysosomal Glucocerebroside-specific Enzyme [EPC] | 2 | 0.0003 |
| 2 | Poly(ADP-Ribose) Polymerase Inhibitor [EPC] | 4 | 0.0002 |
| 3 | Somatostatin Analog [EPC] | 1 | 0.0001 |
| 4 | Substance P/Neurokinin-1 Receptor Antagonist [EPC] | 1 | 0.0001 |
| 5 | Microtubule Inhibitor [EPC] | 18 | 0.0001 |
| 6 | CD52-directed Cytolytic Antibody [EPC] | 2 | 0.0001 |
| 7 | Antifibrinolytic Agent [EPC] | 1 | 0.0001 |
| 8 | Platinum-based Drug [EPC] | 27 | 0.0001 |
| 9 | CD19-directed Chimeric Antigen Receptor [EPC] | 1 | 0.0001 |